Meenta Marketplace and Path SpermQT Partner together to raise the Standard of Care for Male Fertility – QNT Press Release

BOSTON, May 12, 2022 /PRNewswire/ — Meenta Inc. and Path Fertility have formed a partnership to feature Path SpermQT™ on the Meenta Marketplace. Path Fertility is focused on making a difference in male reproductive health through its revolutionary epigenetic technology. Its advanced male fertility test, Path SpermQT, goes beyond standard semen analysis parameters to analyze epigenetic quality factors in sperm that can help guide treatment options. Meenta launched an online Marketplace and contracted with top national laboratories to process the tests you need; and is changing how the world can responsibly access testing. This partnership allows men and couples to order Path SpermQT online from the marketplace, provide a specimen in the privacy of their own home, and discreetly send their sample directly to Path Fertility’s lab.

The purpose of Path SpermQT is to raise the standard of care for male fertility testing by providing critical information about underlying epigenetic factors that may impact a sperm’s ability to achieve a successful pregnancy. While typical semen analyses quantify sperm count, concentration, motility and morphology, Path SpermQT gives…

Full story available on

Source link

Recommended For You

About the Author: News Center